Repligen Co. (NASDAQ:RGEN) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. trimmed its stake in shares of Repligen Co. (NASDAQ:RGEN) by 1.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,091 shares of the biotechnology company’s stock after selling 102 shares during the quarter. Advisors Asset Management Inc.’s holdings in Repligen were worth $1,353,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Andra AP fonden purchased a new position in Repligen in the 2nd quarter valued at $25,000. Lazard Asset Management LLC boosted its holdings in shares of Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 136 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares during the period. Blue Trust Inc. raised its holdings in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in Repligen in the 2nd quarter valued at approximately $33,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.20% of the company’s stock.

Repligen Stock Up 2.4 %

RGEN stock opened at $146.06 on Tuesday. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company’s 50 day simple moving average is $140.26 and its 200-day simple moving average is $143.12. The firm has a market capitalization of $8.18 billion, a PE ratio of -394.59, a P/E/G ratio of 4.29 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the previous year, the company posted $0.23 EPS. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. Equities analysts expect that Repligen Co. will post 1.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. UBS Group cut their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday. Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. JPMorgan Chase & Co. upped their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Finally, Stephens reiterated an “overweight” rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.